WithdrawnPhase 1NCT03605238

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

Studying Neuromyelitis Optica

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chinese PLA General Hospital
Principal Investigator
Quangang Xu, PhD
Chinese PLA General Hospital
Intervention
Corticosteroids & tanCART19/20(biological)
Eligibility
12-75 years · All sexes
Timeline
2018 – 2020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03605238 on ClinicalTrials.gov

Other trials for Neuromyelitis Optica

Additional recruiting or active studies for the same condition.

See all trials for Neuromyelitis Optica →

← Back to all trials